(MedPage Today) — Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
Adjusted annualized rate of vaso-occlusive crises leading to healthcare visits was 2.49 with the standard…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/114658
Author :
Publish date : 2025-03-14 16:13:00
Copyright for syndicated content belongs to the linked Source.
